Abstract
Current drug regulation in Japan is based on the Pharmaceutical Affairs Law, which was revised and strengthened in 1980. This paper describes the drug monitoring system in Japan, with emphasis on postmarketing surveillance. It covers Japan's reexamination policy for new drugs; reporting systems for adverse drug reactions; and the impact of good postmarketing surveillance practice, which became a requirement in April 1993.
Get full access to this article
View all access options for this article.